|Website / URL
|Company: SOMAÍ Pharmaceuticals Next Generation Biotech
|Michael Sassano is one of the most respected executives in the pharmaceutical cannabis space today. He was an early investor in the cannabis industry in the United States; today he is celebrated in mainstream business and biopharma media as an international authority on developing large-scale cannabis infrastructures throughout the world and the most advanced pharmaceutical cannabinoid products. Michael is also widely respected for successfully predicting long term cannabis market trends and movements, which he generously shares in many forums. He is well known for leading a merger of the cannabis cultivation company he built and operated, called Solaris Farms, with The Sanctuary. Over the last few years, Michael has shifted focus to his role as CEO and Chairman of the Board for Somai Pharmaceuticals LTD, a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout EU.
|Tell us your best small idea for big business wins
|Developing many products rather than a few products will prove to be the biggest small idea win for Somai Pharmaceuticals. We could have gone the road of all our competitors and made one product that fits all, but we decided that a simple approach of more products will create a bigger win for our companies future. Pharmaceutical development companies generally put all their eggs in one or two baskets but cannabis has so many uses and so many variations for the uses that one size cannot fit all. Learning from US recreational were 1000’s of products and flowers drive the $33 billion market not one or two dominant products shaped our company strategy to reach farther by more is better philosophy.
|Tell us about you and your background
|I’m a work-a-holic who never made a family and is dedicated full-time to each and every start-up I create. Investors trust in my budgeting and drive to make each venture successful. And my focus everyday is dedicated to the start-up from morning till night, weekends with little time wasted on anything other than me taking care of my health and mind.
|Business is all about overcoming obstacles and creating opportunities for growth. What do you see as the real challenge right now?
|The pharmaceutical cannabis market is in early stages as doctors and patients are just starting to learn how to prescribe and use cannabis to create specific ailments. Creating pharmaceutical medicines is tough enough, but educating doctors is a full-time process. Both are required to grow the market. Of course, regulations are always an obstacle, but sometimes it’s best to ignore political banter and keep your head down and concentrate on the creating products that help patients and educate their doctors to help their patients with the right products.
|On a lighter note, if you had the ability to pick any business superpower, what would it be and how would you put it into practice?
|As a CEO, you’re always using powers of reading into the future, focus etc but if you do not develop the super SALES power you cannot tell the story of your company and its products. Some of the best CEO’s are also the face of their product and they are consumed with getting the story of the products out to the public. Activate super sales powers as a CEO and your companies message will resonate with investors as well as consumers.
|What does “success” in 2023 mean to you? It could be on a personal or business level, please share your vision.
|2023 is the year of making products for Somai Pharmaceuticals. We are registering over 70 medical products this year which is 60 more than our nearest competitor. Our success will be in having the largest pharmaceutical pipeline for cannabis products in the global cannabinoid markets. The more products we register, the more treatments for patients, the greater diversity of revenues lines Somai will have for late 2023, 2024 and beyond. This is a massive undertaking and a very aggressive approach to a new and up-and-coming extracted medical global Pharma cannabis market.